PubMed Search headings:
 (“Shock, Hemorrhagic“[Mesh] OR “Shock, Traumatic“[Mesh] OR “Wounds, Penetrating“[Mesh] OR
"Multiple Trauma"[Mesh] OR “Resuscitation“[Mesh]) AND ("Blood Coagulation"[Mesh] OR "Blood
Coagulation Disorders"[Mesh]) AND “humans“[Mesh]“)
 (“Shock, Hemorrhagic“[Mesh] OR “Shock, Traumatic“[Mesh] OR “Wounds, Penetrating“[Mesh] OR
"Multiple Trauma"[Mesh] OR “Resuscitation“[Mesh]) OR ("Blood Coagulation"[Mesh] OR "Blood
Coagulation Disorders"[Mesh]) AND “humans“[Mesh] with "Blood Transfusion"[Mesh], “Fresh
Frozen
Plasma”,
concentrates
"Platelet
"[Substance
Transfusion"[Mesh],
Name],
"Fibrinogen"[Mesh],
"Antifibrinolytic
Agents"[Mesh],
"prothrombin
"Deamino
complex
Arginine
Vasopressin"[Mesh], "Factor XIII"[Mesh], "recombinant FVIIa "[Substance Name]), respectively
Some statistical details of the mentioned publications:
3.3.2. Fresh frozen plasma
 [53]: almost doubled risk of TRALI (47.1% vs. 24.0%, p=0.001)
 [54]: ventilator-associated pneumonia with shock (relative risk, RR 5.42, CI 2.73-10.74), ventilatorassociated pneumonia without shock (RR 1.97, CI 1.03-3.78), bloodstream infection with shock
(RR 3.35, CI 1.69-6.64) and undifferentiated septic shock (RR 3.22, CI 1.84-5.61); relative risk for
transfusion of FFP and all infections was 2.99 (CI 2.28-3.93)
 [55]: 1–5 FFP of 1.66 (CI 0.88-3.15) and with >5 FFP of 2.55 (CI 1.17–5.55)
3.3.3. FFP:RBC ratio
 [56]: reduction in early coagulopathy (p=0.023), mortality within 24h (17% vs. 36%, p=0.008),
mortality within 30 days for blunt trauma (34% vs. 55%, p=0.04)
 [57]: survival advantage in patients requiring massive transfusion (26% vs. 87.5%, p=0.0001)
 [58]: severity of coagulopathy at ICU admission was associated with survival outcome (p=0.02;
area under receiver operator curve [ROC] =0.71)
 [59]: reduced 30-day mortality for massively transfused patients with ≥2:3 (41% vs. 62%, p=0.008)
 [60]: 30 day survival (40.4% vs. 59.9%, p<0.01); increased 6h, 24h and 30 day survival, as well as
increased ICU-, ventilator- and hospital-free days (p<0.05)
 [61]: Median FFP:RBC in survivors was 1:2, in non-survivors 1:4 (p<0.001)
 [62]: FFP:pRBC of <1:1, 1:1, or >1:1 (6-h: 3.5 % vs. 9.6% vs. 24.6%, p<0.0001; 24-h: 11.3% vs.
16.7% vs. 32.6%, p<0.0001; 30-d: 24.3% vs. 35.1% vs. 45.5%, p<0.001)
 [53]: 24h survival benefit (3.9% vs. 12.8%, p=0.012), increased risk of TRALI (47.1% vs. 24.0%,
p=0.001)
 [65]: reduced 24h mortality (RR 0.37, 95%-CI 0.22–0.64); exact time of transfusion within the first
24h (RR 0.84, 95%-CI 0.47–1.50)
 [66]: improved 6h mortality (from 37.3 [in the lowest ratio group] to 15.7 [in the middle ratio group]
to 2.0% [in the highest ratio group] and 22.8% to 19.0% to 3.2%, respectively) and in-hospital
mortality (from 54.9 to 41.1 to 25.5% and 43.7% to 46.8% to 27.4%, respectively)
3.3.4. Massive transfusion protocol
 [67,68]: reduction in the odds of mortality (p=0.001); higher 30 day survival (56.8% vs. 37.6%,
p<0.001), reduction in hospitalisation time (12 days vs. 16 days, p=0.049) and ventilator days (5.7
days vs. 8.2 days, p=0.017)
 [56]: 24h (previously 36% vs. 14%, p=0.008) and 30d (previously 55% vs. 34%, p=0.04) survival
and caused less deaths from coagulopathy (previously 21/31 vs. 4/13, p=0.023)
3.3.5. Platelets
 [60]: increased 30 day survival with PLT:pRBC ≥1:2 (40.1% vs. 59.9%, p<0.01)
 [66]: 6h survival: 22.8% vs. 19% vs. 3.2%, p<0.002; hospital survival: 43.7% vs. 46.8% vs. 27.4%,
p<0.03
3.3.6. Fibrinogen
 [74]: diminish blood loss (p<0.05); requirements for RBC (p<0.0001), FFP (p<0.0001) and platelet
substitution (p<0.001)
 [75]: improved 7 day survival (p=0.014)
 [79]: reduced blood loss (240 ml, range 50–830 vs. 1800 mL, range 1500–2500, p<0.0001) and
survival of all pigs (p<0.0001)
3.3.7. Prothrombin complex concentrates
 [80]: time to haemostasis after either bone (p=0.001) or spleen (p=0.028) trauma in animals;
reduced volume of blood lost (p<0.001 and p=0.015, respectively); accelerated haemostasis
(p=0.003) and diminished blood loss (p=0.006).
 [81]: improved haemostasis (venous bone trauma p=0.001; arterial spleen trauma p=0.028) and
blood loss (venous bone trauma p=0.001; arterial spleen trauma p=0.015)
3.3.8. Antifibrinolytics
 [3]: all-cause mortality (14.5% TxA vs. 16.0% placebo; RR 0.91; 95% CI 0.85–0.97; p=0.0035),
mortality due to bleeding (4.9% vs. 5.7%; RR 0.85: 95% CI 0.76–0.96; p=0·0077), vascular
occlusive events (1.7% vs. 2.0%)
3.3.9. Desmopressin
 [86]: incidence of myocardial infarct in the DDAVP-treated group (odds ratio [OR], 2.07; CI 0.745.85; p=0.19)
 [89]: reduction in blood loss (weighted mean difference WMD = -386 mL, 95%-CI = -542 to -231 mL
per patient; p=0.0001) and transfused RBC (WMD = -340 mL, 95%CI = -547 to -134 mL per
patient; p=0.0001).
3.3.11. Recombinant activated factor VII
 [97]: decreased 24h mortality (14% vs. 35%, p=0.01) and 30d mortality (31% vs. 51%, p=0.03)
 [98]: reduction in RBC transfusion (estimated reduction of 2.6 RBC units, p=0.02) and need for
massive transfusion (>20 units of RBCs; 14% vs. 33% of patients; p=0.03)
 [99]: costs were significantly lower in the group that received rFVIIa (mean US $108,900 vs.
$77,907);
 [101]: additional blood transfusions (OR 0.54; 95%-CI 0.34–0.86); mortality may be reduced (OR
0.88; 95%-CI 0.71–1.09); reduction in mortality if rFVIIa was given therapeutically (OR 0.87; 95%CI 0.70–1.09); arterial thromboemboli in patients receiving rFVIIa (OR 1.50; 95%-CI 0.93–2.41).
3.3.12. Antithrombin (AT)
 [107]: risk of bleeding events (1.52, CI 1.30–1.78), no reduction in overall mortality (RR 0.96, 95%CI 0.89–1.03)